Ashwani Verma Reiterates Buy on Insmed as Brinsupri’s Measured but Durable Launch Underpins Long-Term Growth Potential

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Insmed, with a price target of $166.00.

Ashwani Verma has given his Buy rating due to a combination of factors linked to Brinsupri’s early launch dynamics and long‑term potential. Feedback from a leading center of excellence suggests that adoption is progressing in a measured but durable fashion, with a meaningful share of eligible bronchiectasis patients expected to eventually receive the drug, supporting a sustained revenue ramp rather than a short‑lived surge.

Strong adherence in well‑informed settings, low discontinuation from side effects, and high overall payer approval reinforce confidence that utilization can scale over time. While acknowledging variability in patient expectations and isolated access or competitive risks, Verma views these as manageable relative to the magnitude of the addressable population and Insmed’s positioning, making the current valuation attractive on a risk‑reward basis.

In another report released on May 14, Truist Financial also maintained a Buy rating on the stock with a $185.00 price target.